[Federal Register Volume 59, Number 170 (Friday, September 2, 1994)]
[Notices]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-21742]


[[Page Unknown]]

[Federal Register: September 2, 1994]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

 

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:

    Pantelis Constantoulakis, Advanced BioScience Laboratories, Inc.: 
The Division of Research Investigations (DRI) of the Office of Research 
Integrity (ORI) reviewed an investigation conducted by Advanced 
BioScience Laboratories (ABL) into possible scientific misconduct on 
the part of Mr. Constantoulakis while an employee of ABL at the 
Frederick Cancer Research and Development Center. ORI concurred with 
the factual findings as set forth in the ABL report, and finds that Mr. 
Constantoulakis committed scientific misconduct by falsifying and 
fabricating data in biomedical research supported by a contract with 
the National Cancer Institute and by misrepresenting his academic 
credentials for purposes of his employment under the contract. Mr. 
Constantoulakis accepted the misconduct finding and agreed to a 
Voluntary Exclusion and Settlement Agreement under which Mr. 
Constantoulakis will not apply for Federal grant or contract funds and 
will not serve on PHS advisory committees, boards, or peer review 
groups for a five-year period beginning August 2, 1994.
    One published paper (Science: 259:1314-1318) which contained data 
that was not reproducible has been retracted (Science: 264:492).

FOR FURTHER INFORMATION CONTACT:
Director, Division of Research Investigations, Office of Research 
Integrity, 301-443-5330.

Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 94-21742 Filed 9-1-94; 8:45 am]
BILLING CODE 4160-17-M